AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize compounds and products, including epetraborole for the treatment, diagnosis, or prevention of various human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize compounds and products comprising epetraborole in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases; and GSK plc for the development of new therapies for TB. AN2 Therapeutics, Inc. was incorporated in 2017 and is headquartered in Menlo Park, California.…
AN2 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business and Scientific Highlights
AN2 Therapeutics (NASDAQ: ANTX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 21 employees.
The shares were at 5.080 USD on 20 November 2026, up 345.6% over 52 weeks. Its 52-week range is 1.000 USD to 7.190 USD: the price is 29.3% below the high and 408.0% above the low.
Its market capitalisation is 192.75M USD.
AN2 Therapeutics reports return on equity of -66.3% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 64.40M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 2 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 9.000 USD is 77.2% above the current price.